Dec 5 (Reuters) - Replimune Group said on Tuesday its experimental drug to treat a common form of skin cancer did not meet the main goals in a late-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Arun Koyyur)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.82 USD | -2.00% | +58.63% | +4.63% |
Jun. 07 | HC Wainwright Adjusts Price Target on Replimune to $17 From $12, Maintains Buy Rating | MT |
Jun. 06 | Sector Update: Health Care Stocks Higher in Late Afternoon Trading | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.63% | 542M | |
+48.54% | 56.61B | |
-6.02% | 39.62B | |
+37.09% | 39.25B | |
-6.90% | 28.28B | |
+12.97% | 26.44B | |
-16.91% | 20.12B | |
+28.18% | 12.51B | |
+31.71% | 12.48B | |
+0.38% | 12.2B |
- Stock Market
- Equities
- REPL Stock
- News Replimune Group, Inc.
- Replimune's skin cancer drug fails in late-stage study